SynthesisFrontiers in oncology2025
The impact of BRCA mutation and hormone receptor status on the outcomes of fertility preservation in breast cancer patients: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fertility preservation in young women with breast cancer: a narrative review of effectiveness, oncologic safety, and clinical practice implications.Annals of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fertility preservation is a critical aspect of care for young breast cancer (BC) patients undergoing gonadotoxic treatments. BRCA mutation and hormone receptor (HR) status influence tumor biology and treatment outcomes. This study evaluated the impact of BRCA mutation and HR status on fertility preservation outcomes in BC patients. Methods: PubMed, Embase, Scopus, and Web of Science databases were searched for publications from inception to March 31, 2025 that report on fertility preservation outcomes stratified by BRCA mutation or HR status. Primary outcomes included the number of retrieved oocytes, maturation rates, and ovarian reserve indices such as anti-Müllerian hormone (AMH) levels and antral follicular count (AFC). Random-effects meta-analyses were performed. Results: Thirteen studies involving approximately 1,654 participants were included in the meta-analysis. Patients with no BRCA mutations reported significantly higher mature oocytes (MD: -1.48, 95% CI: -2.63 to -0.34) compared to those with BRCA mutations and non-significant total oocyte yield (MD: -1.37, 95% CI: -3.13 to 0.40). AFC and AMH levels showed no significant intergroup differences. Additionally, estrogen receptor (ER)-positive patients exhibited better ovarian response, with higher AFC (MD: 1.37, 95% CI: 0.48 to 2.26) and greater oocyte yield (MD: 1.35, 95% CI: 0.67 to 2.02). Conclusion: Our results show that BRCA mutations may be associated with significantly diminished mature oocyte production during fertility preservation in BC patients. On the contrary, ER-positive status seems to be associated with high AFC and oocyte yield indicating a more advantageous ovarian response. The present findings are from a limited number of heterogenous studies and hence must be interpreted with caution. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42025641361.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.